Aguilar-Rubido JC, A van de Klundert MA, Michel Marie-Louise

Language: Spanish
References: 0
Page: 2511-2521
PDF size: 424.23 Kb.

ABSTRACT

The International Liver Congress 2017 (ILC2017) was celebrated on April 19-23, 2017 at the RAI Convention Center in Amsterdam, The Netherlands. The ILC2017 covered new developments, research updates and technological advancements in the field of liver diseases. The consolidation of the hepatitis C treatment revolution has led to the approval of direct acting antivirals and their implementation in public health. The impetuous development in the field of chronic hepatitis C is now being followed by an increase in the therapeutic strategies for chronic hepatitis B. The developments of innovative therapies against viral hepatitis are presented in this report, with a special focus on the most clinically advanced chronic hepatitis B treatments. Novel strategies for CHB and global efforts lead by the World Health Organization are also considered, such strategies aimed to prevent disease progression and mortality by liver cirrhosis (LC) and hepatocellular carcinoma (HCC) as a result of viral hepatitis. Moreover, the most relevant issues presented in the 2017 update of the guidelines of the European Association for the Study of the Liver for CHB management are highlighted, considering the discussions taking place during the launching session at the ILC2017 meeting.